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Abstract
Background: The Th17 subset and IL-17 have been found in increased frequencies within certain tumors.
However, their relevance in cancer biology remains controversial. This study aimed to clarify the biological action
of IL-17 on hepatocellular carcinoma (HCC).
Methods: Effects and underlying molecular mechanisms of IL-17 on human HCC were explored in vitro using
exogenous IL-17 stimulation and in nude mice by implanting IL-17 overexpressed HCC cells. The clinical
significance of IL-17 was investigated in tissue microarrays containing HCC tissues from 323 patients following
hepatectomy using immunohistochemistry.
Results: Although exogenous IL-17 showed no direct effect on the growth rate of HCC cells in vitro, PCR and
ELISA showed that IL-17 selectively augmented the secretion of diverse proinvasive factors and transwell showed a
direct promotion of invasion of HCC cells by IL-17. Furthermore, transfection of IL-17 into HCC cells significantly
promoted neoangiogenesis, neutrophil recruitment and tumor growth in vivo. Using siRNA mediated knockdown
of AKT and STAT3, we suggested that the effects of IL-17 were operated through activation of the AKT signaling in
HCC, which resulted in IL-6 production. Then, IL-6 in turn activated JAK2/STAT3 signaling and subsequently up-
regulated its downstream targets IL-8, MMP2, and VEGF. Supporting these findings, in human HCC tissues,
immunostaining indicated that IL-17 expression was significantly and positively associated with STAT3
phosphorylation, neutrophil infiltration and increased tumor vascularity. The clinical significance of IL-17 was
authenticated by revealing that the combination of intratumoral IL-17+ cells and phospho-STAT3 served as a better
prognosticator for postoperative tumor recurrence than either marker alone.
Conclusions: IL-17 mediated tumor-promoting role involves a direct effect on HCC cells through IL-6/JAK2/STAT3
induction by activating the AKT pathway.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most common cause of can-
cer-related death globally [1]. Despite advances in
treatment modalities, long-term survival of HCC patients
remains unsatisfactory because of the high rate of recur-
rence and metastasis [1]. HCC is usually secondary to
inflammatory conditions due to chronic hepatitis and
cirrhosis resulting from either hepatitis B/C virus infec-
tion or from non viral-related causes such as alcohol or
obesity. Compelling evidence has shown that inflamma-
tion orchestrates the microe n v i r o n m e n ta r o u n dH C C ,
making a significant difference to cancer cell prolifera-
tion, migration, and survival [2].
T helper 17 (Th17) cells are an important inflammatory
component whose main physiological role is to promote
host defense against infectious agents, and are well
appreciated for contributing to autoimmune diseases [3].
Recently, Th17 cells and its signature cytokine, interleu-
kin-17 (IL-17), have been found increased frequencies
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between Th17 cells and tumor immunopathology has
been controversial [7,8]. Both beneficial and detrimental
direct and indirect effects of IL-17 occurred in context
and tumor system dependent manners. Transfection of
IL-17 into tumor cells augmented the progression of the
disease in nude mice via the effects on vascular endothe-
lium and increased neoangiogenesis [9,10]. In contrast,
the same kind of experiments using syngeneic tumors in
immunocompetent mice induced tumor suppression or
even eradication by facilitating the recruitment of effector
immune cells [11]. In clinical settings, a significant
inverse correlation has been found between Th17 cell dif-
ferentiation and prostate/ovarian cancer progression
[4,12], and low dose cyclophosphamide has newly been
shown to modulate the tumor microenvironment by
decreasing Treg suppressors while favoring Th17 and
Th1 cells [13]. In HCC, IL-17+ T cells have been found
in increased numbers within tumors and correlate with
poor survival and increased postoperative recurrence,
indicating that Th17 cells and IL-17 may promote tumor
progression in HCC [14]. However, the direct effects and
the underlying mechanisms of IL-17 in modulating
human HCC cell growth remain elusive.
Previous studies have shown that IL-17 supported
tumor progression via the effects on immune cells, vascu-
lar endothelial cells and stromal cells, focusing mostly on
stimulating angiogenesis and inflammation. Given that
many types of tumor cells bear IL-17 receptor alpha (IL-
17RA) [15,16], the specific receptor for IL-17, IL-17 may
have a direct impact on the biological behavior of tumor
cells in the local microenvironment. As a confirmation,
in murine B16 melanoma and MB49 bladder carcinoma,
IL-17 mediated tumor-promoting role involves a direct
effect on tumor cells through IL-6 induction and subse-
quent signal transducer and activator of transcription 3
(STAT3) activation [15]. IL-6 and other members of the
IL-6 family of cytokines, including IL-11, in activating the
JAK-STAT3 pathway leading to cancer-promoting
inflammation has been widely documented [17]. It is
well-known that cytokines’ role in regulating tumor pro-
gression and metastasis are highly cell-type-dependent
and context-dependent, highlighting that the effects of
IL-17 on HCC cells mandate specific investigation. Thus,
in this study, we attempted to elucidate the exact role
and associated molecular mechanism of IL-17 in HCC
proliferation and invasion in vitro and in nude mice. The
clinical relevance and prognostic significance of IL-17 in
human HCC were also investigated.
Materials and methods
Cell lines
Two human HCC cell lines, SMMC7721 (a human HCC
cell line with low metastatic potential, established by the
Shanghai Institute of Cell Biology, Chinese Academy of
Sciences, Shanghai, China) [18] and Huh7 (a well-differ-
entiated and non-metastatic human HCC cell line, Japa-
nese Cancer Research Resources Bank), were maintained
in high-glucose Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), L-glutamine, 100 units/ml penicil-
lin, and 100 μg/ml streptomycin. All cell lines were cul-
tured at 37°C in a humidified incubator in 5% CO2.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA was extracted with Trizol Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’sp r o t o c o l ,
and reversed transcribed with RevertAid™ first-strand
cDNA synthesis kit (Fermentas, Burlington, ON). IL-17
and IL-17RA mRNA levels were determined by qPCR
using SYBR Premix Ex Taq (TaKaRa, Dalian, China) and
normalized with b-actin using the following primers: IL-17
forward, 5’-CGC TGA TGG GAA CGT GGA CTA C-3’
and reverse, 5’-GGT GGA CAA TCG GGG TGA CA-3’.
IL-17R forward, 5’-GTT CAT CAC GGG CAT CTC CAT
C-3’ and reverse, 5’-CAG GCA GGC CAT CGG TGT
ATT-3’. b-actin forward, 5’-CAA CTG GGA CGA CAT
GGA GAA AAT-3’ and reverse, 5’-CCA GAG GCG TAC
AGG GAT AGC AC-3’. The relative gene expression was
calculated with the 2
-ΔCt method.
MTT, cell migration, and matrigel invasion assays
The effect of IL-17 on HCC cell growth was determined
with the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-
liumbromide (MTT) assay. Cells were seeded into 96-
well flat-bottom plates (1 × 10
3/ w e l l )a n dc u l t u r e df o r1
to 4 days in medium supplemented with recombinant
human IL-17 (0, 0.1, 0.5, 1, 5, 10, 50, 100, or 500 ng/ml; 6
wells/dose), and each experiment was repeated at least
three times. After IL-17 treatment, cells were incubated
with MTT (20 μl / w e l l )a t3 7 ° Cf o r4h ,a n dt h e n2 0 0μl
dimethylsulfoxide was added. The absorbance of indivi-
dual wells was determined at 570 nm.
The wound-healing assay was used to evaluate the ability
of cell migration. Cells were grown to 80-90% confluence in
24-well plates, and a wound was made by dragging a plastic
pipette tip across the cell surface. The remaining cells were
washed three times to remove cell debris, and then incu-
bated at 37°C with serum-free medium. After 48 h, migrat-
ing cells at the wound front were photographed and
compared. Three separate experiments were performed.
Cell invasion assays were performed using 24-well
transwells (8-μm pore size; Minipore) precoated with
Matrigel (BD Biosciences, San Jose, CA). In total, 1 × 10
5
cells, which were suspended in 100 μl DMEM containing
hIL-17 (50 ng/ml), 1% FBS, IL-6 mAb (10 ng/ml), and/or
IL-6 (100 ng/ml), were added to the upper chamber, and
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lower chamber. After 36 h of incubation, Matrigel and
the cells remaining in the upper chamber were removed
using cotton swabs. Cells on the lower surface of the
membrane were fixed in 4% paraformaldehyde and
stained with Giemsa. Cells in five microscopic fields (at
200× magnification) were counted and photographed. All
experiments were performed in triplicate.
Recombinant human IL-17 and IL-6, and an IL-6 neu-
tralizing mAb (R&D Systems) were applied as appropriate.
Immunofluorescence staining, ELISA, and western blot
analysis
For immunofluorescence staining, the monoclonal anti-
body (mAb) IL-17RA (R&D Systems, Minneapolis, MN)
was used.
The levels of IL-6, IL-1b,T N F - a, TGF-b, IL-8, G-CSF,
GM-CSF, VEGF, and MMP2 in culture supernatants were
measured by ELISA, following the manufacturer’s instruc-
tions (R&D Systems). Intra- and inter-assay coefficients of
variation were < 5% and < 10%, respectively.
Western blotting was performed as previously described
[19]. The specific primary antibodies p-JAK2 (Y1007/
1008), JAK2, p-STAT3 (Y705), STAT3, p-p65 NF-B
(S536), p65 NF-B, p-AKT (S473), AKT, p-JNK (T183/
Y185), JNK, p-ERK1/2 (T202/Y204), ERK1/2, p-p38
MAPK (T180/Y182) and p38 MAPK (Cell Signaling Tech-
nology, Beverly, MA), as well as MMP2 (Abcam, Cam-
bridge, MA) were used. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Millipore, Billerica, MA) was
used as a loading control.
Cell transfection and clone selection
STAT3- and AKT-targeted siRNAs, as well as negative
control mismatch sequences, were synthesized by Shang-
hai GeneChem Co. using the following sense and anti-
sense strands: AKT sense, GUG CCA UGA UCU GUA
UUU ATT and anti-sense, UAA AUA CAG AUC AUG
GCA CTT; STAT3 sense, GGG ACC UGG UGU GAA
UUA UTT and anti-sense, AUA AUU CAC ACC AGG
UCC CTT. Transfection into SMMC7721 and Huh7 cells
was performed using Lipofectamine™ 2000 (Invitrogen)
according to the manufacturer’s instructions.
The pEGFP-N1-IL-17 plasmids were also constructed
by Shanghai GeneChem Co. and pEGFP-N1 plasmids
were used as controls. The lentiviral vector and plasmid
were transfected into SMMC7721 cells as described
elsewhere [20]. Stably transfected clones were validated
by qRT-PCR and immunoblotting for the level of target
gene expression (Additional file 1, Figure S1).
Animal experiments
B A L B / c am a l en u d em i c e( S h a n g h a iI n s t i t u t eo fM a t e r i a
Medica, Chinese Academy of Science), 4 to 6 weeks old,
were kept in laminar-flow cabinets under specific patho-
gen-free conditions, cared for, and handled according to
the recommendations of the National Institutes of Health
guidelines for care and use of laboratory animals. The
experimental protocol was approved by Shanghai Medical
Experimental Animal Care Committee. For the tumor
challenge, 1 × 10
6 SMMC7721-IL-17 or SMMC7721-
mock tumor cells were injected subcutaneously into nude
mice, and tumor growth was monitored each week [21].
There were five animals in each group. The mice were
sacrificed on day 28 after tumor implantation. The levels
of IL-6, IL-8, VEGF, and MMP2 in mice serum were mea-
sured by ELISA. Tumor tissues were prepared for Western
blot analysis and immunostaining. Anti-mouse CD31 and
Gr-1 mAbs (Abcam) were used for immunostaining.
Patients and follow-up
Tumor samples were obtained from 410 patients with
pathologically confirmed HCC at Liver Cancer Institute of
Zhongshan Hospital, Fudan University. Serial sections
from 87 patients (cohort 1) treated between December
2010 and January 2011 were used for immunohistochem-
istry, among which 48, 21, and 18 patients were classified
as TNM stage I, II, and III, respectively [22]. For tissue
microarray (TMA) construction, archived tissues were
obtained from 323 consecutive HCC patients treated
between January 2003 and March 2004, with a median fol-
low-up of 60 months (range, 2.0-74.0 months; cohort 2).
All patients demonstrated no distant metastasis and had
not received anticancer therapy before surgery. The tumor
stage was determined according to the 2010 American
Joint Committee on Cancer and International Union
Against Cancer tumor-node-metastasis (TNM) classifica-
tion system. Tumor differentiation was graded by the
Edmondson grading system. The follow-up procedure was
performed as described in our previous report [23]. Over-
all survival (OS) or time to recurrence was defined as the
intervals between the dates of surgery and death or the
first recurrence, respectively. Patients without death or
recurrence were censored at the last follow up. Detailed
clinicopathological characteristics are given in Table S1.
Ethical approval was obtained from the research ethics
committee of Zhongshan Hospital and written informed
consent was obtained from each patient.
Tissue microarrays and immunohistochemistry
To examine the relationship between the densities of
intratumoral IL-17+ cells and CD66b+ neutrophils or
microvessel densities (MVDs), 87 cases (cohort 1) were
chosen for immunohistochemistry using serial whole
tumor sections.
TMAs were constructed as described elsewhere
[19,23] using tissues form cohort 2 (n = 323). Immuno-
histochemistry was conducted with the following
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mouse antihuman CD66b (BD Pharmingen, San Diego,
CA) and CD34 (Abcam), and rabbit antihuman
p-STAT3 (Y705) (Cell Signaling Technology). Blank
controls were treated identically with primary antibodies
omitted.
The capture of the photographs and measurement of
positive staining density were performed as described pre-
viously [23]. Briefly, for IL-17, p-STAT3, and CD66b stain-
ing in consecutive sections from 87 HCC patients (cohort
1) and Gr-1 staining in xenografts, the sections were
stained with indicated antibodies, and then were evaluated
using light microscopy at 200× or 400× magnification by
two investigators. Five representative fields of each case
were captured. IL-17+ cell density or CD66b+ and Gr-1+
neutrophil density was evaluated according to the mean
number of positive-staining cells in five count areas. For
expression intensity of p-STAT3, the integrated absor-
bance and the area in a photograph were measured using
Image-Pro Plus v6.0 software (Media Cybernetics, Inc.). A
uniform setting of color segmentation was loaded for
counting the integrated absorbance of all the pictures, and
the mean p-STAT3 density was calculated as the product
of the integrated absorbance/total area.
A Ki-67-specific monoclonal rat antibody (DAKO A/S)
was used for detection and quantitation of tumor cell pro-
liferation, while the In Situ Cell Death Detection kit-Per-
oxidase (Roche) was used for detection and quantitation
of apoptosis. The Proliferation Index and Apoptosis Index
were determined by calculating the number of Ki-67- or
TUNEL-positive cells per total number of cells (hematoxy-
lin-positive plus Ki-67- or TUNEL-positive cells) in 5 ran-
domly selected fields at ×200, using Image-Pro Plus v6.0
software as previously described [19].
For the MVD, sections were stained with CD31 or CD34
antibody and a diaminobenzidine reaction system for
immunohistochemical assessment of tumor microvessels
in five randomly selected fields at 200× magnification. The
average number of microvessels was calculated. For the
microvessel count, any brown-stained endothelial cell or
endothelial cell cluster that was clearly separated from
adjacent microvessels, tumor cells, and connective ele-
ments was counted as one microvessel, irrespective of the
presence of a vessel lumen [4].
IL-17 and p-STAT3 staining in TMAs were evaluated
at 200× magnification using light microscopy by two
investigators blinded to the clinicopathologic data of the
patients. For IL-17 immunostaining, the number of posi-
tive staining cells in each 1-mm diameter cylinder were
calculated manually and expressed as the mean number
of the duplicates (cells/1-mm core). For the expression
intensity of p-STAT3, the integrated absorbance and the
area in each 1-mm diameter cylinder were measured
using Image-Pro Plus v6.0 software. The mean p-STAT3
density was calculated as the product of the integrated
absorbance/total area.
Statistical analysis
Statistical analysis was performed with SPSS 16.0 software
(SPSS, Chicago, IL). Measurement values were expressed
as means ± standard deviations. Student’s t test, c
2 test,
and Spearman’s r correlation were used as appropriate.
The cumulative recurrence and survival rates were per-
formed by the Kaplan-Meier method (log-rank test). Cox
multivariate analysis with a stepwise method (forward,
likelihood ratio) was used to determine the independent
prognostic factors. Two-tailed p < 0.05 was judged to be
significant.
The median value of IL-17+ cell counts was used as
the cutoff to dichotomize IL-17 immunostaining. The
optimal cutoff for dichotomizing p-STAT3 (Y705)
expression data was determined using X-tile 3.6.1 soft-
ware (Yale University of New Haven) [24].
Results
IL-17 promotes HCC invasion and migration in vitro
The expression of IL-17RA was easily detectable by
qRT-PCR and immunofluorescence in Huh7 and
SMMC7721 cells (Figure 1A). Because IL-17+ T cells
were significantly elevated in HCC patients and corre-
lated with poor survival [14], we thus assumed that IL-
17 could stimulate HCC cells through IL-17RA signaling
pathways. Although IL-17 exerted little influence on cell
proliferation (Additional file 2, Figure S2A), wound-
healing assays revealed an evident increase in the wound
closure rates of Huh7 and SMMC7721 cells after IL-17
(50 ng/ml) stimulation for 48 h (Figure 1B), and matri-
gel invasion assays showed that exogenous IL-17 (50 ng/
ml for 36 h) significantly promoted the invasion of
Huh7 and SMMC7721 cells (Figure 1C). These results
indicated that IL-17 can promote invasion and migra-
tion of HCC in vitro.
IL-17 up-regulates proinvasive factors in HCC in vitro
IL-17 is known for eliciting secretion of diverse inflam-
matory mediators in diverse cell types, including stromal
cells and tumor cells. We found that IL-17 selectively
up-regulated the production of IL-6, IL-8, MMP2, and
VEGF in Huh7 and SMMC7721 cells (Table 1). The
most prominent secretion was IL-6, with 5.8- and 6.0-
fold increases, serially followed by IL-8 (2.5- and 5.6-
fold), MMP2 (1.5- and 1.6- fold) and VEGF (1.2- and
1.7- fold) in Huh7 and SMMC7721 cells respectively. By
contrast, in Huh7 and SMMC7721 cells, the production
of IL-1b,T N F - a, TGF-b, G-CSF and GM-CSF were not
significantly affected by exogenous IL-17.
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Various signaling pathways are suggested to mediate IL-
17 action. Here, we scrutinized the potential signaling
pathways of IL-17 action in HCC cells and found that
IL-17 had no effect on p38 MAPK, ERK, JNK and p65
NF-B activation in Huh7 and SMMC7721 cells (Addi-
tional file 2, Figure S2B). Intriguingly, phosphorylation
of STAT3 and AKT were obviously increased as early as
3 h after IL-17 treatment and lasted for 24 h (Figure
2A, and Additional file 3, Figure S3A). Given that
expression of IL-6, IL-8, MMP2, and VEGF increased in
parallel with STAT3 and AKT activation in HCC cells
treated with IL-17, STAT3, and AKT signaling may play
important roles in inducing these proinvasive factors
and hence tumor progression.
IL-17 promotes HCC progression via AKT-dependent IL-6/
STAT3 activation
To explore the potential role of STAT3 and AKT in IL-
17-mediated effects on HCC, STAT3 and AKT expres-
sion were reduced by small interfering RNA (siRNA).
First, in HCC cells exposed to STAT3-targeted siRNA
(HCC-siRNA-STAT3), IL-17-induced AKT phosphoryla-
tion was not affected, while in HCC cells exposed to
AKT-targeted siRNA (HCC-siRNA-AKT), IL-17-induced
STAT3 phosphorylation was significantly reduced
Figure 1 IL-17 promotes invasion and migration of HCC in vitro. (A) As assessed by immunofluorescence staining and RT-PCR, IL-17RA
expression was easily detectable in HCC cell lines (400× magnification). (B) Wound-healing assays revealed an evident increase in the wound
closure rates of Huh7 and SMMC7721 cells after IL-17 (50 ng/ml) stimulation for 48 h (100× magnification). (C) Matrigel invasion assays showed
that IL-17 (50 ng/ml for 36 h) significantly promoted the invasion of Huh7 and SMMC7721 cells [migration cell numbers (control vs IL-17); 37.00
± 5.29 vs 75.67 ± 6.11, p = 0.001 for Huh7; 49.00 ± 4.00 vs 104.67 ± 13.61, p = 0.002 for SMMC7721; 200× magnification]. Each experiment was
repeated at least three times. Student’s t test was used.
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S3C). Furthermore, IL-17-induced AKT phosphorylation
was obviously increased as early as 5 minutes after IL-
17 treatment, while phosphorylation of JAK2 and
STAT3 were not affected during the 60 minutes treat-
ment (Figure 2D). These results suggested that AKT
phosphorylation was an earlier event as compared with
STAT3 phosphorylation in HCC stimulated with IL-17.
Additionally, in HCC-siRNA-STAT3 cells, IL-17-
induced expression of IL-8, MMP2, and VEGF were sig-
nificantly inhibited, while IL-17-induced IL-6 upregula-
tion was not affected (Figure 2B and 2E, and Additional
file 3, Figure S3B and S3D). These results indicated that
IL-8, MMP2, and VEGF were target genes instead of the
upstream activators of STAT3. Furthermore, neutraliz-
ing IL-6 with a blocking mAb reduced JAK2 and
Table 1 IL-17 affects the production of inflammatory cytokines of HCC
Huh7 (pg/ml) SMMC7721 (pg/ml)
IL-17 (50 ng/ml) - + p - + p
IL-6 7.0 ± 1.5 40.5 ± 19.6 < 0.001 63.3 ± 33.8 380.9 ± 198.2 0.001
IL-1b 5.3 ± 0.4 5.53 ± 0.5 0.397 6.4 ± 1.6 5.6 ± 1.0 0.261
TNF-a 22.5 ± 2.3 21.3 ± 1.2 0.206 22.8 ± 3.3 26.6 ± 6.0 0.137
TGF-b 215.7 ± 51.9 206.5 ± 47.5 0.716 140.7 ± 83.2 143.6 ± 41.5 0.931
IL-8 25.4 ± 13.1 141.3 ± 133.9 0.029 208.9 ± 144.5 521.7 ± 208.3 0.004
G-CSF 10.9 ± 1.2 11.4 ± 2.0 0.575 20.3 ± 14.9 39.3 ± 28.1 0.112
GM-CSF 6.5 ± 0.5 8.3 ± 3.8 0.212 8.40 ± 2.23 15.3 ± 9.9 0.078
VEGF 2236.4 ± 300.3 3814.5 ± 1188.6 0.043 332.0 ± 157.7 557.8 ± 162.2 0.014
MMP2 327.6 ± 12.2 492.8 ± 44.5 < 0.001 351.4 ± 14.3 558.6 ± 91.2 < 0.001
ELISA-determined cytokine levels were expressed as mean ± SD. p-values were calculated by Student’s t test.
Figure 2 IL-17 activates AKT and IL-6/STAT3, and up-regulates proinvasive factors production in SMMC7721 cells. (A) Western blotting
showed that phosphorylation of JAK2, STAT3 and AKT were obviously increased as early as 3 h after IL-17 treatment and lasted for 24 h after IL-
17 stimulation. SMMC7721 cells were incubated with IL-17 at the indicated concentrations for 24 h or at 50 ng/ml for the indicated time. (B and
C) Cells were cultured for 24 h with IL-17 (50 ng/ml). In siRNA-STAT3-SMMC7721 cells, IL-17-induced AKT and JAK2 phosphorylation were not
affected, while in siRNA-AKT-SMMC7721, IL-17-induced JAK2/STAT3 phosphorylation was significantly reduced. (D) IL-17-induced AKT
phosphorylation was obviously increased as early as 5 minutes after IL-17 treatment, while phosphorylation of JAK2 and STAT3 were not affected
during the 60 minutes treatment. (E) HCC cells were cultured for 24 h with IL-17 (50 ng/ml) and/or IL-6 mAb (10 ng/ml), and concentrations of
the proinvasive factors in culture supernatants were measured by ELISA. IL-17 selectively up-regulated the production of IL-6, IL-8, MMP2 and
VEGF by tumor cells. Both IL-6 mAb and siRNA-STAT3 significantly downregulated the expression of IL-8, MMP2 and VEGF, while IL-17-induced
IL-6 upregulation was not altered. (F) IL-6 mAb reduced STAT3 activation, whereas AKT activation by IL-17 was not affected. Data are expressed
as mean ± SD; Student’s t test; # p > 0.05; *p < 0.05, **p < 0.01, and ***p < 0.001.
Gu et al. Molecular Cancer 2011, 10:150
http://www.molecular-cancer.com/content/10/1/150
Page 6 of 13STAT3 activation and inhibited upregulation of IL-8,
MMP2, and VEGF by IL-17, whereas AKT activation by
IL-17 was not affected (Figure 2E and 2F, and Addi-
t i o n a lf i l e3 ,F i g u r eS 3 Da n dS 3 E ) .T h u s ,I L - 6m a yb e
the main upstream activator, rather than the down-
stream target of JAK2/STAT3, in the setting of IL-17
stimulation.
By contrast, in HCC-siRNA-AKT cells, but not HCC-
siRNA-STAT3 cells, IL-17-induced IL-6 upregulation
was significantly blocked (Figure 2E and 3A, and Addi-
tional file 3, Figure S3D and Additional file 4, S4A).
Thus, AKT siRNA both repressed IL-6 and downregu-
lated JAK2/STAT3 phosphorylation induced by IL-17
(Figure 2C, 3A and 3B, and Additional file 3, Figure S3C,
Additional file 4, S4A and S4B), indicating that IL-6/
JAK2/STAT3 may be the targets of AKT in the context
of IL-17. Thus, IL-17 may upregulate IL-6 production via
AKT activation. IL-6 in turn activates JAK2/STAT3 and
subsequently stimulates IL-8, MMP2, and VEGF produc-
tion. Supporting this hypothesis, JAK2/STAT3
phosphorylation and the expression of IL-8, MMP2, and
VEGF were significantly increased after addition of IL-17
plus exogenous IL-6 in siRNA-AKT-SMMC7721 and
siRNA-AKT-Huh7 cells (Figure 3A and 3C, and Addi-
tional file 4, Figure S4A and S4C).
Meanwhile, STAT3-siRNA significantly reversed tumor
invasion by IL-17 stimulation in HCC (Figure 3D, and
Additional file 4, Figure S4D). An IL-6 neutralizing mAb
reduced STAT3 activation and also completely reversed
IL-17-stimulated tumor invasion in vitro (Figure 3D, and
Additional file 4, Figure S4D), while exogenous IL-6 com-
pletely recovered IL-17-induced invasion of siRNA-AKT-
SMMC7721 and siRNA-AKT-Huh7 cells (Figure 3D, and
Additional file 4, Figure S4D). AKT-dependent IL-6/
STAT3 activation was therefore suggested to be responsi-
ble for the tumor promoting effects of IL-17 on HCC.
IL-17 promotes HCC progression in vivo
When tumor cells were injected into nude mice, the
growth rate of SMMC7721-IL-17 tumors was drastically
Figure 3 IL-17 promotes HCC invasion via AKT-dependent IL-6/STAT3 activation. SMMC7721 cells were exposed to AKT-targeted or STAT3-
targeted siRNA, and then cultured with IL-17 (50 ng/ml) and/or IL-6 (100 ng/ml) for 24 h. (A) As assessed by ELISA, the expression of IL-6, IL-8,
MMP2 and VEGF showed no significant change after IL-17 stimulation in siRNA-AKT-SMMC7721 cells, while expression of IL-8, MMP2 and VEGF
were significantly increased after addition of IL-17 plus IL-6. (B) AKT-siRNA significantly downregulated JAK2/STAT3 phosphorylation induced by
IL-17. (C) IL-6 also recovered IL-17-stimulated JAK2/STAT3 phosphorylation in siRNA-AKT-SMMC7721 cells. (D) As shown by Matrigel invasion
assay, STAT3-siRNA significantly reversed tumor invasion by IL-17 stimulation. IL-6 mAb (10 ng/ml for 36 h) completely reversed IL-17-induced
HCC invasion, while IL-6 (100 ng/ml for 36 h) completely recovered IL-17-stimulated invasion of siRNA-AKT-SMMC7721 cells. Three separate
experiments were performed in each study. Data are expressed as mean ± SD; Student’s t test; # p > 0.05; *p < 0.05, **p < 0.01, and ***p <
0.001.
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tumor volume (mock vs IL-17), 0.589 ± 0.259 vs 4.175 ±
3.050 cm
3, p = 0.031; mean tumor weight (mock vs IL-
17), 0.392 ± 0.124 vs 2.140 ± 0.963 g, p = 0.004; respec-
tively; Figure 4A]. Moreover, SMMC7721-IL-17-derived
xenografts showed increased tumor cell proliferation
while reduced apoptosis of HCC cells compared with
the SMMC7721-mock group [proliferation index (mock
vs IL-17), 71.260 ± 9.584 vs 83.820 ± 6.549, p = 0.042;
apoptosis index (mock vs IL-17), 1.070 ± 0.222 vs 0.626
± 0.320, p = 0.034; respectively; Additional file 5, Figure
S5].
Increased phosphorylation of AKT was evident and the
plasma concentration of IL-6 was significantly up-regu-
lated in IL-17-transfected SMMC7721 mice compared
with those in controls (Figure 4B and 4C). Overexpres-
sion of IL-17 also promoted JAK2/STAT3 activation and
markedly up-regulated production of IL-8, MMP2, and
VEGF (Figure 4B and 4C).
Apart from direct effects on tumor cells, MMP2 and
VEGF are known for fostering angiogenesis and IL-8 is
a major chemotactic factor for neutrophil recruitment.
Supporting this, SMMC7721-IL-17-derived xenografts
presented with more neoangiogenesis (CD31+) and Gr-1
+ neutrophil infiltration than the SMMC7721-mock
group (p < 0.001 for both; Figure 4D).
Intratumoral IL-17+ cells positively correlate with p-STAT3
intensity, neutrophil and microvessel densities
Because in vivo SMMC7721-IL-17 tumors were character-
ized by increased angiogenesis and enriched neutrophil
infiltration, we further explored whether a similar
phenomenon exists in human HCC tissues. By staining
consecutive sections in 87 HCC patients (Figure 5A), a
correlation analysis revealed that significant positive corre-
lations were found between the density of intratumoral IL-
17-producing cells and MVD (r = 0.567; p < 0.001), as well
as between the densities of intratumoral CD66b+ neutro-
phils and IL-17+ cells (r = 0.630; p < 0.001; Figure 5B).
Additionally, the p-STAT3 intensity significantly and posi-
tively correlated with levels of intratumoral IL-17+ cells,
CD66b+ neutrophils, and MVD (r = 0.324 and p = 0.002; r
= 0.350 and p < 0.001; r = 0.544 and p < 0.001; respec-
tively; Additional file 6, Figure S6). Thus, IL-17+ cells may
promote neoangiogenesis andn e u t r o p h i lr ecruitment
partly via STAT3 activation in human HCC.
Figure 4 IL-17 promotes HCC progression in nude mice. (A) The tumor growth rate of SMMC7721-IL-17 was drastically increased relative to
SMMC7721-mock [mean tumor volume (mock vs IL-17), 0.589 ± 0.259 vs 4.175 ± 3.050 cm
3, p = 0.031; mean tumor weight (mock vs IL-17),
0.392 ± 0.124 vs 2.140 ± 0.963 g, p = 0.004; respectively]. (B) Overexpression of IL-17 promoted STAT3 and AKT activation in xenografts. (C)
Overexpression of IL-17 markedly up-regulated production of IL-6, IL-8, MMP2 and VEGF in mice serum as measured by ELISA. (D)
Neoangiogenesis and neutrophil recruitment in xenografts were assayed with CD31 (200× magnification) and Gr-1 staining (400× magnification).
SMMC7721-IL-17-derived xenografts showed increased neoangiogenesis and neutrophil infiltration compared with the SMMC7721-mock group.
Data are expressed as mean ± SD; Student’s t test; **p < 0.01, and ***p < 0.001.
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Page 8 of 13Figure 5 Clinical relevance and prognostic value of IL-17+ cells. (A and B) Serial whole tumor sections from 87 HCC patients were used
and representative cases of immunostaining of IL-17, p-STAT3, CD34 (MVD) and CD66b (neutrophils) are shown (200× magnification). Significant
positive correlations were found between the intratumoral IL-17+ cell density and MVD, as well as between the densities of intratumoral
neutrophils and IL-17+ cells. (C and D) 323 HCC patients contained in TMAs were classified into three groups: group I, high expression of both
IL-17+ cells and p-STAT3; group II, high expression of one of the two markers; and group III, low expression of both markers. The intratumoral IL-
17+ cell density significantly was correlated with p-STAT3 expression in this cohort as well. The 1-, 3-, and 5-year survival and cumulative
recurrence rates in group I were significantly lower than those in groups II and III. Correlations between immunostaining parameters were
analyzed by Spearman’s rho coefficient test. The cumulative recurrence and survival rates were determined by the Kaplan-Meier method (log-
rank test).
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prognostic marker
We further investigated the prognostic value of IL-17 and
its target, p-STAT3, both separately and in combination,
in TMA containing 323 HCC patients (Additional file 7,
Figure S7). Similarly, the density of intratumoral IL-17+
cells significantly correlated with p-STAT3 expression in
this cohort (r = 0.315; p < 0.001; Figure 5C). Both IL-
17
high and p-STAT3
high were significantly correlated with
microvascular invasion (p = 0.016 and p = 0.013, respec-
tively; Additional file 8, Table S1).
Among the 323 patients, the 5-year OS and cumulative
recurrence rates were 50.7% and 59.7%, respectively. Uni-
variate analysis revealed that intratumoral IL-17+ cells and
p-STAT3 expression were significantly associated with
recurrence and survival (Table 2). Furthermore, patients
were classified into three groups: group I, high expression
of both markers; group II, high expression of either mar-
kers; and group III, low expression of both markers. Signif-
icant differences in recurrence and survival were detected
among the three groups (Figure 5D).
Significant clinicopathologic features identified in uni-
variate analysis were adopted as covariates in multivari-
ate Cox models. Multivariate analyses showed that IL-17
+ cell and p-STAT3 expression independently correlated
with OS and recurrence, irrespective of being used
alone or in combination (Additional file 9, Table S2).
However, concomitant high of IL-17 and p-STAT3 was
superior to either marker alone in terms of hazard ratios
and p values for both OS and recurrence (Additional
file 9, Table S2). In multivariate analysis where IL-17+
cells, p-STAT3 expression and their combination were
simultaneously adopted as covariates (Table 2), only
their combination remained statistically significant. Spe-
cifically, compared with group III, hazard ratios of
group I were 2.244 (95% CI, 1.529-3.293; p < 0.001) for
death and 1.718 (95% CI, 1.193-2.473; p = 0.004) for
recurrence (Table 2), respectively.
Discussion
IL-17 has been shown to be elevated in several types of
cancer, but how it might contribute to tumor growth is
still unclear. Here, we found that IL-17 selectively aug-
mented the secretion of various proinvasive factors and
directly promoted in vitro invasion of HCC. Furthermore,
transfection of IL-17 into HCC cells significantly pro-
moted neoangiogenesis, neutrophil recruitment and
tumor growth in vivo. These effects of IL-17 were sug-
gested to be operated through activation of the AKT sig-
naling, which resulted in IL-6 production. Then, IL-6 in
turn activated JAK2/STAT3 signaling and subsequently
up-regulated its downstream targets IL-8, MMP2, and
VEGF. Supporting these findings, in human HCC tissues,
IL-17 expression was significantly and positively asso-
ciated with STAT3 phosphorylation, neutrophil infiltra-
tion, and increased tumor vascularity. Our findings thus
Table 2 Univariate and multivariate analyses of factors associated with survival and recurrence
Overall survival Cumulative recurrence
Multivariate Multivariate
Variables Univariate: P HR (95%CI) P Univariate: P HR (95%CI) P
Age, years (≤ 51 vs > 51) NS NA NA NS NA NA
Gender (female vs male) 0.032 NA NS 0.013 1.765 (1.078-2.891) 0.024
HBsAg (no vs yes) NS NA NA NS NA NA
Liver cirrhosis (no vs yes) NS NA NA NS NA NA
a-Fetoprotein (≤ 20 vs > 20 ng/mL) 0.016 NA NS NS NA NA
Tumor diameter (≤ 5v s>5c m ) < 0.001 2.192 (1.583-3.035) < 0.001 < 0.001 1.613 (1.183-2.200) 0.003
Tumor number (single vs multiple) 0.037 NA NS 0.136 NA NS
Tumor encapsulation (none vs complete) 0.001 1.478 (1.073-2.034) 0.017 0.001 1.532 (1.126-2.084) 0.007
Tumor differentiation (I/II vs III/IV) 0.009 1.581 (1.118-2.237) 0.010 NS NA NA
Vascular invasion (no vs yes) < 0.001 1.965 (1.413-2.732) < 0.001 < 0.001 1.591 (1.157-2.188) 0.004
TNM stage (I vs II/III) < 0.001 NA NA < 0.001 NA NA
IL-17
low vs IL-17
high 0.001 NA NS 0.018 NA NS
p-STAT3
low vs p-STAT3
high < 0.001 NA NS 0.011 NA NS
Combination of IL-17 and p-STAT3*
Overall < 0.001 NA < 0.001 < 0.001 NA 0.009
Iv sI I 0.001 NA NS NS NA NS
I vs III < 0.001 2.244 (1.529-3.293) < 0.001 0.001 1.718 (1.193-2.473) 0.004
Note: Univariate analysis was calculated using the Kaplan-Meier method (the log-rank test). Multivariate analysis was performed using the Cox multivariate
proportional hazard regression model with a stepwise method (forward, likelihood ratio).
Abbreviations: HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; NA, not assessed; NS, not significant; TNM, tumor-node-metastasis.
*I, IL17
high and p-STAT3
high; II, IL17
high p-STAT3
low or IL17
low p-STAT3
high; III, IL17
low and p-STAT3
low
.
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promote HCC progression.
Previous studies have shown that IL-17 has diverse
effects on inflammatory cells and stromal cells, focusing
mostly on stimulating angiogenesis and inflammation
[9-11]. Recently, in primary hepatocytes, IL-17 was shown
to up-regulate a group of inflammatory cytokine genes,
most of which are NF-B target genes [25]. Given that the
expression of IL-17RA was considerable in HCC cells, we
thus hypothesize that IL-17-mediated tumor-promoting
role involved a direct effect on HCC cells. Supporting this,
we found that exogenous IL-17 directly promoted HCC
cell invasion in vitro and enhances tumor progression in
vivo. Although consistent with several recent publications
regarding the role of IL-17 in promoting tumor growth,
these findings contradict other reports suggesting that IL-
17 can provide an antitumor effect against certain tumors
[4,11]
The means by which IL-17 achieves its effects, either for
the benefit or the detriment of the host, are largely due to
the induction of new gene expression. However, different
cell types appear to respond differently to IL-17 in terms
of target gene expression. More recently, IL-17 has been
also reported to mediate the release of proinflammatory
factors and chemokines from tumor cells, including renal,
lung and cervical cancers [10,26,27]. Here, we showed that
IL-17 selectively up-regulated the production of proinva-
sive factors in HCC cells, including IL-6, IL-8, MMP2, and
VEGF. As master regulators of cell dissemination, prolif-
eration and angiogenesis, the production of these factors
from HCC cells inevitably resulted in the progression of
HCC. By contrast, although GM-CSF, G-CSF, TNF-a,
TGF-b and IL-1b have been reported to be affected by IL-
17 in other cell types [28], production of these cytokines
in HCC cells was not significantly altered under IL-17.
IL-17 mediates signaling through distinct pathways in
numerous inflammatory cells and tumor cells, such as
MAPK, NF-B, and STAT3 pathways [16]. We found
that IL-17 significantly induced STAT3 and AKT phos-
phorylation, but had no obvious effect on p38 MAPK,
ERK, JNK and p65 NF-B activation in HCC cells.
These indicated that STAT3 and AKT activation play an
important role in the induction of proinvasive factors
and hence tumor progression. Previously, IL-17 has
been reported to stimulate production of IL-6 and
STAT3 activation in inflammatory cells and fibroblasts
in an autoimmune disease [29], as well as in cancer cells
[15,30]. Furthermore, IL-6 mediated activation of
STAT3 in tumor cells results in increases in anti-apop-
totic, pro-proliferation, and pro-angiogenic genes [31].
In this study, using siRNA-mediated AKT and STAT3
knockdown, our data further extended these findings by
indicating that IL-17 stimulated IL-6 induction was
attributed to the activation of the AKT pathway; IL-6 in
turn activated JAK2/STAT3 and up-regulated the tran-
scription of the proinvasive genes. Our results were con-
sistent with the hypothesis that, under certain
conditions, AKT signaling may be the new proximal sig-
naling mediator used by the IL-17R family to mediate
downstream events [16,32,33]. To the best of our knowl-
edge, this study is the first to demonstrate that IL-17-
induced IL-6/STAT3 activation was dependent on the
activation of the AKT signaling pathway in tumor cells.
Because previous studies suggested the opposite role
of IL-17 in tumor systems in nude mice versus immu-
nocompetent mice [9-11], we further verified whether
our finding in the xenograft nude mouse HCC model
could be reproducible in human HCC. We found that
intratumoral IL-17-producing cells were positively and
significantly correlated with intratumoral neutrophils
and MVD, not only in transplanted HCC model but
also in human HCC tissues. The results supported that
aside from direct promotion effects on tumor invasion
and migration, IL-17 could also promote tumor angio-
genesis and neutrophil recruitment through induction of
HCC cells to releasing angiogenic and chemotactic fac-
tors such as IL-8, MMPs and VEGF. Alternatively, IL-17
may directly affect vascular endothelial cells and recruite
circulating neutrophils by serving as neutrophil chemo-
tactic and angiogenic factors, which were correlated
with poor prognosis in HCC [34,35]. Furthermore, the
levels of IL-17+ cells positively correlated with the
expression of p-STAT3, both of which were associated
with the presence of microvascular invasion, and poor
survival in HCC patients. The combination of intratu-
moral IL-17+ cells and p-STAT3 expression served as a
better predictor than either used alone in HCC patients.
Conclusions
In conclusion, our results suggested that the IL-17
mediated tumor-promoting role involved a direct effect
on tumor cells through IL-6 induction by activating the
AKT pathway; IL-6 in turn activated JAK2/STAT3 and
up-regulated proinvasive factors IL-8, MMP2, and VEGF
both in vitro and in vivo. Therapies that target IL-17
and STAT3 may be developed as potential therapeutic
approaches to inhibit HCC.
Additional material
Additional file 1: Figure S1 SMMC7721 cells are stably transfected
with lentiviral-mediated pEGFP-N1-IL-17 plasmids. The pEGFP-N1-IL-
17 plasmids were constructed and pEGFP-N1 plasmids were used as
controls. The lentiviral vector and plasmid were transfected into
SMMC7721 cells. SMMC7721 cells were successfully transfected with
pEGFP-N1-IL-17 plasmids validated by fluorescent imaging (A), qRT-PCR,
and immunoblotting (B) for the level of IL-17 expression.
Additional file 2: Figure S2 IL-17 shows no effect on tumor
proliferation, as well as p38 MAPK, ERK, JNK, and p65 NF-B
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Page 11 of 13activation in vitro. (A) IL-17 had no effect on tumor proliferation as
assessed by the MTT assay. Cells were cultured for 1 to 4 days in
medium supplemented with IL-17 (0, 0.1, 0.5, 1, 5, 10, 50, 100 or 500 ng/
ml). (B) Huh7 and SMMC7721 cells were incubated with IL-17 (50 ng/ml)
for the indicated time. As assessed by Western blot analysis, IL-17
showed no effect on p38 MAPK, ERK, JNK, and p65 NF-B activation.
Additional file 3: Figure S3 IL-17 activates AKT and IL-6/STAT3, and
up-regulates proinvasive factors production in Huh7 cells. (A)
Western blotting showed that phosphorylation of JAK2, STAT3 and AKT
were obviously increased as early as 3 h after IL-17 treatment and lasted
for 24 h after IL-17 stimulation. Huh7 cells were incubated with IL-17 at
the indicated concentrations for 24 h or at 50 ng/ml for the indicated
time. (B and C) Cells were cultured for 24 h with IL-17 (50 ng/ml). In
siRNA-STAT3-Huh7 cells, IL-17-induced AKT and JAK2 phosphorylation
were not affected, while in siRNA-AKT- Huh7, IL-17-induced JAK2/STAT3
phosphorylation was significantly reduced. (D) HCC cells were cultured
for 24 h with IL-17 (50 ng/ml) and/or IL-6 mAb (10 ng/ml), and
concentrations of the proinvasive factors in culture supernatants were
measured by ELISA. IL-17 selectively up-regulated the production of IL-6,
IL-8, MMP2 and VEGF by tumor cells. Both IL-6 mAb and siRNA-STAT3
significantly downregulated the expression of IL-8, MMP2 and VEGF,
while IL-17-induced IL-6 upregulation was not altered. (E) IL-6 mAb
reduced STAT3 activation, whereas AKT activation by IL-17 was not
affected.
Additional file 4: Figure S4 IL-17 promotes HCC invasion via AKT-
dependent IL-6/STAT3 activation. Huh7 cells were exposed to AKT-
targeted or STAT3-targeted siRNA, and then cultured with IL-17 (50 ng/
ml) and/or IL-6 (100 ng/ml) for 24 h. (A) As assessed by ELISA, the
expression of IL-6, IL-8, MMP2 and VEGF showed no significant change
after IL-17 stimulation in siRNA-AKT-Huh7 cells, while expression of IL-8,
MMP2 and VEGF were significantly increased after addition of IL-17 plus
IL-6. (B) AKT-siRNA significantly downregulated JAK2/STAT3
phosphorylation induced by IL-17. (C) IL-6 also recovered IL-17-
stimulated JAK2/STAT3 phosphorylation in siRNA-AKT-Huh7 cells. (D) As
shown by Matrigel invasion assay, STAT3-siRNA significantly reversed
tumor invasion by IL-17 stimulation. IL-6 mAb (10 ng/ml for 36 h)
completely reversed IL-17-induced HCC invasion, while IL-6 (100 ng/ml
for 36 h) completely recovered IL-17-stimulated invasion of siRNA-AKT-
Huh7 cells. Three separate experiments were performed in each study.
Additional file 5: Figure S5 IL-17 promotes tumor cell proliferation
and inhibites apoptosis of HCC cells in nude mice. Proliferation index
and apoptosis index in xenografts were assayed with Ki-67 and TUNEL
staining (200× magnification). SMMC7721-IL-17-derived xenografts
showed increased tumor cell proliferation while reduced apoptosis of
HCC cells compared with the SMMC7721-mock group.
Additional file 6: Figure S6 The intratumoral p-STAT3 intensity is
positively correlated with IL-17+ cell, neutrophil and microvessel
densities. Serial whole tumor sections from 87 HCC patients were used
for immunostaining. The intratumoral p-STAT3 staining intensity was
significantly and positively correlated with the levels of intratumoral IL-17
+ cells, neutrophils, and MVD. Correlations between immunostaining
parameters were analyzed by Spearman’s rho coefficient test.
Additional file 7: Figure S7 Representative cases of
immunohistochemical staining of IL-17 and p-STAT3 in a tissue
microarray. Consecutive sections of case 1 and case 2 showed high IL-
17+ cells and p-STAT3 staining, while consecutive sections of case 3 and
4 showed low IL-17+ cells and p-STAT3 staining.
Additional file 8: Table S1 Correlation between IL-17 or p-STAT3
and clinicopathological characteristics. Both IL-17
high and p-STAT3
high
were significantly correlated with microvascular invasion.
Additional file 9: Table S2 Multivariate analyses of prognosis factors
associated with survival. IL-17+ cell and p-STAT3 expression
independently correlated with OS and recurrence, irrespective of being
used alone or in combination. However, concomitant high of IL-17 and
p-STAT3 was superior to either marker alone in terms of hazard ratios
and p values for both OS and recurrence.
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